hormone response to growth hormone-releasing hormone (GHRH), insulin, clonidine and arginine after GHRH pretreatment in obese children: evidence of somatostatin increase? Eur J Endocrinol 1995; 132:716-21. ISSN To clarify the possible neuroendocrine mechanisms underlying the impairment in growth hormone (GH) secretion present in obesity, the GH response to GH-releasing hormone (GHRH, N = 6), insulin hypoglycemia (N = 6), clonidine (N = 7) and arginine (N = 8) after GHRH pretreatment (1 \g=m\g/kg iv 2 h before the tests) was evaluated in 27 obese peripubertal children and in a group of normal-weight short-normal children (N = 26). Growth hormone-releasing hormone pretreatment and all further stimuli elicited a statistically significant GH response in both obese and short-normal children; in the latter group arginine did not induce a significant GH response. No differences were found among the GH responses after the second stimuli in obese children, while in short-normal children the arginine peak and area values were lower than after GHRH and clonidine. Comparison between the two groups showed similar baseline but higher stimulated GH levels in normal-weight children after all tests except ariginine, after which no difference was present. In conclusion, the neuroregulation of GH release seems to be similar qualitatively in normal-weight and obese youngsters; the different behavior observed after arginine, which is supposed to act through somatostatin inhibition, might be due to a chronic increase in somatostatinergic tone responsible for the lower stimulated GH levels in obesity. 
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Sergio Bernasconi In overweight humans the fact that pyridostigmine, an SRIH inhibitor, is able to restore partially the GH responsiveness to GHRH suggests that an SRIH increase is present in obesity (6) (7) (8) . On the other hand, it has also been shown that repeated prestimulations by GHRH increase the GH response to the releasing hormone, indicating that all altered release and/or action of endogenous GHRH could be present (9) . This latter hypothesis is against the evidence that in obese subjects GH peak amplitudes, but not the peak number, are lower than in controls, suggesting again an increase in SRÍH levels (10) .
Finally, other authors (11) indicate peripheral factors such as insulin, IgF-I or free fatty acids as responsible for the negative feedback at the pituitary and hypothalamic levels.
In children, a different GH neuroregulation compared with adults has been described (12, 13 (12, 13 (18) have shown that the opioid system could be involved in clonidinemediated GH secretion, we can speculate that the elevated basal levels of /9-endorphins reported in obese youngsters (19) 
